Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
(Thomson Reuters ONE) -
Novartis International AG /
Alcon introduces new innovations in cataract surgery at European Society of
Cataract & Refractive Surgeons 2017 annual congress
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Clareon(® )intraocular lens (IOL) implanted with a unique single-use
automated pre-loaded delivery system debuts with new data presentations
* Congress program highlights Alcon's 70-year legacy of innovation including
100 million AcrySof(® )IOL implants
* New analyses show efficacy and safety of CyPass(®) Micro-Stent in patients
with glaucoma
Basel, October 2, 2017 - Alcon, the global leader in eye care and a division of
Novartis, will introduce Clareon(®), the intraocular lens (IOL) with the most
advanced optic material available in an automated, disposable, pre-loaded
delivery system, at the XXXV European Society of Cataract & Refractive Surgeons
(ESCRS) congress taking place October 7 - 11 in Lisbon, Portugal. In addition,
Alcon will deliver an extensive scientific and educational program including 18
accepted abstracts and more than 10 satellite events covering its latest
innovations in cataract, refractive and glaucoma surgery.
"We are proud to deliver on our commitment to bring innovations to the surgical
community, and Clareon(®) is one of the biggest breakthroughs in the IOL space,"
said Mike Ball, Chief Executive Officer, Alcon. "This is a great year for Alcon
as we celebrate many important milestones - from fulfilling our mission to help
people see better by enhancing and transforming the way surgeons treat cataracts
through innovations like Clareon(®), to marking the 100 millionth implant of our
flagship AcrySof(®) lenses."
Alcon's full scientific and educational program includes symposia, presentations
and stand-alone events, highlighting the Clareon(®) monofocal IOL and its novel
delivery system, and the benefits of treating concomitant visual conditions such
as astigmatism, presbyopia and glaucoma along with cataracts using the
AcrySof(®) family of IOLs and the CyPass(®) Micro-Stent.
As part of the ESCRS Glaucoma scientific program, further analysis of the
COMPASS and CyCLE clinical studies on the CyPass(®) Micro-Stent will be
presented. The CyPass(®) Micro-Stent is a minimally invasive glaucoma surgical
(MIGS) device, indicated for the treatment of patients with mild-to-moderate
primary open-angle glaucoma in conjunction with cataract surgery, or as a
standalone procedure in patients with primary open-angle glaucoma who have
failed previous medical treatments.
Recently launched in European markets, CyPass(®) Micro-Stent is the first MIGS
device designed to be implanted in the supraciliary space, utilizing the same
outflow pathway as first-line prostaglandin analog medications and providing an
additional option to meet the needs of millions of glaucoma patients.
Additional information about these products will be available at the Alcon booth
#P272 in the exhibition area of the Feira Internacional de Lisboa (FIL) congress
center.
Program highlights
Symposia:
* Friday, October 6
* Alcon Glaucoma Symposium: A Closer Look: CyPass(®) - Innovation in MIGS
via the Supraciliary Space - Moderated by Prof. Keith Barton (1:00 -
2:00 p.m., Room 3.1, FIL congress center)
* Sunday, October 8
* Alcon Advanced Technologies Symposium: Bridging the Gap to Cataract
Refractive Surgery - Moderated by Prof. Rudy Nuijts (1:00 - 2:00 p.m.,
Room 4.7, FIL congress center)
* Alcon INFOCUS symposium: Two minutes to better surgery! Debating the
topics most important to your techniques - Moderated by Prof. Antoine
Brezin (Welcome reception and event: 6:00 - 8:00 p.m., Room 4.1, FIL
congress center)
* Monday, October 9
* Alcon Cataract Symposium - Clareon(®) IOL: A new IOL Platform -
Moderated by Prof. Rudy Nuijts (1:00 - 2:00 p.m., Room 4.7, FIL congress
center)
Paper and poster presentations:
* Saturday, October 7
* Scientific Poster Presentation: Multicenter Defocus Curve Evaluation of
a Novel Trifocal Presbyopia-Correcting IOL: 6 Months Post-Op Results,
Dr. T. Kohnen (2:32 - 2:40 p.m., Poster Village, Pod 1, FIL congress
center)
* Monday, October 9
* Scientific Paper Presentation: Ocular Hypotensive Medication Use in
Patients Undergoing Combined Cataract Surgery and Supraciliary Micro-
Stent Implantation for Open-Angle Glaucoma in the COMPASS Trial, Dr. S.
Sarkisian, Jr. (9:12 - 9:18 a.m., Room 4.1, FIL congress center)
* Scientific Paper Presentation: Three-year Results from the CyCLE Study
for Supraciliary Micro-Stent Implantation Combined with Cataract Surgery
for Open-Angle Glaucoma, Dr. H. Hoh (9:30 - 9:36 a.m., Room 4.1, FIL
congress center)
* Scientific Paper Presentation: Combined Cataract Surgery and
Supraciliary Micro-Stent Implantation for Open-Angle Glaucoma: BCVA
Outcomes from the COMPASS Trial, Dr. T. Ianchulev (9:36 - 9:42 a.m.,
Room 4.1, FIL congress center)
* Tuesday, October 10
* Scientific Paper Presentation: Optical Purity Evaluation and Accelerated
Aging of the New Clareon(®) Biomaterial vs. Other Hydrophobic Acrylic
Material in a Laboratory Setup, Dr. G. Auffarth (3:42 - 3:48 p.m., Room
3.6, FIL congress center)
* Scientific Paper Presentation: Evaluation of Clarity Characteristics in
a New Hydrophobic Acrylic IOL in Comparison with Commercially Available
Lenses, Dr. L. Werner, (3:48 - 3:54 p.m., Room 3.6, FIL congress center)
* Scientific Paper Presentation: Distribution of Preoperative Corneal
Astigmatism and Postoperative Refractive Astigmatism in a Large
Population of Patients Undergoing Cataract Surgery in the UK, Dr. A. Day
(8:30 - 8:36 a.m., Room 4.4, FIL congress center)
* Scientific Poster Presentation: Survey in twelve countries reveals major
gap in cataract awareness, Dr. M. Morral (10:35 - 10:40 a.m., Poster
Village, Pod 1, FIL congress center)
* Scientific Paper Presentation: A Multicentre, Retrospective Cohort Study
Comparing the Real-World Incidence of Nd:YAG Laser Capsulotomy Procedure
to Treat Posterior Capsular Opacification in the First 3 Years after
Cataract Surgery Among Hydrophobic and Hydrophilic Acrylic IOLs, Dr. P.
Ursell (3:02 - 3:08 p.m., Room 4.4, FIL congress center)
* Scientific Paper Presentation: Global Prevalence, Economic and
Humanistic Burden of Astigmatism in Cataract Patients: A Systematic
Literature Review, Dr. D. Anderson (8:36 - 8:42 a.m., Room 4.4, FIL
congress center)
* Electronic poster presentations (available throughout the entire meeting at
the computer terminals):
* Laboratory Evaluation of the New Clareon(®) Hydrophobic Acrylic IOL
Material: Biomaterial Properties and Capsular Bag Behavior, Dr. G.
Auffarth
* Miyake-Apple Posterior View Analysis of Capsular Bag Behavior of the New
Clareon(®) Hydrophobic Acrylic IOL Material, Dr. H. Fang
* Evaluation of the Mechanical Behavior of a New Single-Piece Intraocular
Lens as Compared to Commercially Available IOLs, Dr. S. Lane
* Model Eye and In Vitro Assessment of Positive Dysphotopsia or Glare
Types Photic Phenomena: A Comparison of a New Material IOL to Other
Monofocal Intraocular Lenses, Dr. L. Werner
* Silicone oil adhesion of hydrophobic acrylic intraocular lenses (IOL): A
comparative laboratory study of the new Clareon(®) versus current
AcrySof(®) IOL material, Dr. F. Hengerer
Disclaimer
This press release contains forward-looking statements, including "forward-
looking statements" within the meaning of the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements can generally be
identified by words such as "potential," "can," "will," "plan," "expect,"
"anticipate," "look forward," "believe," "committed," "investigational,"
"pipeline," "launch," or similar terms, or by express or implied discussions
regarding potential marketing approvals, new indications or labeling for the
investigational or approved products described in this press release, or
regarding potential future revenues from such products. You should not place
undue reliance on these statements. Such forward-looking statements are based on
our current beliefs and expectations regarding future events, and are subject to
significant known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that the investigational
or approved products described in this press release will be submitted or
approved for sale or for any additional indications or labeling in any market,
or at any particular time. Nor can there be any guarantee that such products
will be commercially successful in the future. In particular, our expectations
regarding such products could be affected by, among other things, the
uncertainties inherent in research and development, including clinical trial
results and additional analysis of existing clinical data; regulatory actions or
delays or government regulation generally; our ability to obtain or maintain
proprietary intellectual property protection; the particular prescribing
preferences of physicians and patients; global trends toward health care cost
containment, including government, payor and general public pricing and
reimbursement pressures; general economic and industry conditions, including the
effects of the persistently weak economic and financial environment in many
countries; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Alcon
Alcon is the global leader in eye care. As a division of Novartis, we offer the
broadest portfolio of products to enhance sight and improve people's lives. Our
products touch the lives of more than 260 million people each year living with
conditions like cataracts, glaucoma, retinal diseases and refractive errors, and
there are millions more who are waiting for solutions to meet their eye care
needs. Our purpose is reimagining eye care, and we do this through innovative
products, partnerships with eye care professionals and programs that enhance
access to quality eye care. Learn more at www.alcon.com.
Alcon is on Facebook. Like us at www.facebook.com/AlconEyeCare
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
119,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Irina Ferluga
Novartis Global Media Relations Alcon Communications
+41 61 324 7999 (direct) M + 41 79 824 1121
+41 79 593 4202 (mobile) irina.ferluga(at)alcon.com
eric.althoff(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2138316/818590.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 561974
Anzahl Zeichen: 14907
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 319 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
